Aripiprazole, olanzapine and haloperidol pamoate salts

Abstract

The invention relates to the discovery that pamoate salts of haloperidol and aripiprazole result in a good to superior long acting and/or extended release profile. Thus, in one aspect of the invention, the invention includes pamoate salts of haloperidol or aripiprazole. Preferably, the pamoate salt is characterized by a ratio of haloperidol to pamoate of 1:1 or 2:1. The pamoate salt can be crystalline, such as a needle or a dense crystal, such as described in the Figures. The invention further relates to methods of treating an individual in need thereof comprising administering a pharmaceutical composition comprising a pamoate salt of haloperidol and aripiprazole.

1 . A pamoate salt of haloperidol.  
     
     
         2 . The pamoate salt of  claim 1 , wherein the ratio of haloperidol to pamoate is 1:1 or 2:1.  
     
     
         3 . The pamoate salt of  claim 1 , wherein the salt is a needle.  
     
     
         4 . The pamoate salt of  claim 1 , wherein the salt is crystalline.  
     
     
         5 . A pamoate salt of aripiprazole.  
     
     
         6 . The pamoate salt of  claim 4 , wherein the ratio of aripiprazole to pamoate is 1:1 or 2:1.  
     
     
         7 . The pamoate salt of  claim 5 , wherein the salt is crystalline.  
     
     
         8 . A method of treating an individual in need thereof comprising administering a pharmaceutical composition comprising a pamoate salt of an active agent selected from the group consisting of haloperidol and aripiprazole.  
     
     
         9 . The method of  claim 8 , wherein the composition is administered by injection.  
     
     
         10 . The method of  claim 8 , wherein the composition is administered intramuscularly or subcutaneously.  
     
     
         11 . The method of  claim 8 , wherein the composition releases an effective amount of the active agent over a period of at least about 24 hours.  
     
     
         12 . The method of  claim 8 , wherein the composition releases an effective amount of the active agent over a period of at least about 48 hours.  
     
     
         13 . The method of  claim 8 , wherein said composition consists essentially of the pamoate salt and a viscous aqueous carrier.  
     
     
         14 . The method of  claim 8 , wherein said composition is an extended release formulation comprising a biodegradable polymer and the pamoate salt.  
     
     
         15 . The method of  claim 14 , wherein the extended release formulation comprises a polylactide and the pamoate salt.  
     
     
         16 . The method of  claim 14 , wherein the extended release formulation comprises a polylactide-co-glycolide and the pamoate salt.